(Q44666733)

5 December 2017

Use of naltrexone in the treatment of alcoholism nationally in the Department of Veterans Affairs (English)

1 reference

5 December 2017

0 references

0 references

0 references

3

Robert Rosenheck

1 reference

5 December 2017

Ismene L Petrakis

1

1 reference

PubMed ID

14634494

5 December 2017

Douglas Leslie

series ordinal

2

1 reference

5 December 2017

1 November 2003

1 reference

Alcoholism: Clinical and Experimental Research

5 December 2017

1 reference

5 December 2017

27

1 reference

5 December 2017

11

1 reference

5 December 2017

1780-1784

1 reference

Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods

5 December 2017

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000095861.43232.19

Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000095861.43232.19

Naltrexone increases the latency to drink alcohol in social drinkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000095861.43232.19

A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000095861.43232.19

Naltrexone treatment for alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000095861.43232.19

Physicians’ opinions about medications to treat alcoholism

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000095861.43232.19

Naltrexone for alcohol dependence: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000095861.43232.19

Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000095861.43232.19

Prevalence, detection and treatment of anxiety, depression, and delirium in the adult critical care unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000095861.43232.19

Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000095861.43232.19

Naltrexone in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000095861.43232.19

Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F01.ALC.0000095861.43232.19

10.1097/01.ALC.0000095861.43232.19

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference

PubMed ID

14634494